title:  BD Synapsys™ – Insufficient Session Expiration
description: BD Synapsys™, versions 4.20, 4.20 SR1, and 4.30, contain an insufficient session expiration vulnerability. If exploited, threat actors may be able to access, modify or delete sensitive information, including electronic protected health information (ePHI), protected health information (PHI) and personally identifiable information (PII).
problem types: CWE-613 Insufficient Session Expiration
affected:
{
product:  BD Synapsys™
vendor: Becton Dickinson (BD)
versions:
lessThanOrEqual: 4.30, status: affected, version: 4.20 , versionType: custom
}
metrics:
cvssV3_1: [
attackComplexity: LOW
attackVector: PHYSICAL
availabilityImpact: NONE
baseScore: 5.7
baseSeverity: MEDIUM
confidentialityImpact: HIGH
integrityImpact: HIGH
privilegesRequired: LOW
scope: UNCHANGED
userInteraction: REQUIRED
vectorString: CVSS:3.1/AV:P/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:N
version: 3.1
]
solutions: BD Synapsys™ v4.20 SR2 will be released in June 2022 and will remediate this vulnerability. Customers receiving BD Synapsys™ v4.30 will be allowed to upgrade to v5.10, which is expected to be available by August 2022.
workarounds: Configure the inactivity session timeout in the operating system to match the session expiration timeout in BD Synapsys™.
Ensure physical access controls are in place and only authorized end-users have access to BD Synapsys™ workstations.
Place a reminder at each computer for users to logout when leaving the BD Synapsys™ workstation.
Ensure industry standard network security policies and procedures are followed.